Patients with myeloproliferative neoplasms (MPN), a group of malignant bone-marrow disorders, often harbour a cancer-causing, mutated form of the calreticulin (CALR) gene. This specific type of blood cancer is characterised by increased production of blood cells, a susceptibility to thrombosis and frequent progression to acute leukaemia. Scientists from Robert Kralovics’ research group at CeMM (Centre for Molecular Medicine of the Austrian Academy of Sciences) have now identified haematoxylin as a novel CALR inhibitor. Haematoxylin is used in histological staining procedures.
Back in 2013, the same laboratory discovered that these patients frequently carried carcinogenic mutations in the gene, which are now used as medical markers. The mechanism by which these mutations can lead to leukaemia has also been identified. The cancer-causing effect of the mutations is underpinned by the interaction between CALR’s N-glycan-binding domain and the thrombopoietin receptor. Now, the study’s lead author, Ruochen Jia, has shown that a group of chemicals, foremost among them haematoxylin, can selectively kill mutated CALR cells. The findings thus provide valuable insights into potential treatment approaches for myeloproliferative neoplasms
“Our study demonstrates the enormous therapeutic potential of CALR inhibitor therapy,” explains Kralovics. “The treatment of patients with primary myelofibrosis (PMF) continues to yield poor clinical outcomes. They are most likely to develop acute myeloid leukaemia. As around one third of PMF patients have a CALR mutation, they could benefit particularly from this new therapeutic approach.”
References:
CeMM, MedUni Vienna: Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with the thrombopoietin receptor, Blood, 17 November 2020; DOI: https://doi.org/10.1182/blood.2020006264